RX466 High-Heat Phenolic Compound (Rogers Corporation)
Product Description
RX466 was a high-heat phenolic molding compound manufactured by Rogers Corporation, a Connecticut-based specialty materials company that built its industrial reputation on engineered polymer and composite materials. Phenolic compounds of this class were formulated to withstand extreme thermal and electrical stress, making them well-suited for demanding industrial environments where standard thermoplastic materials would fail or degrade rapidly.
Products in the RX466 category were designed as thermoset molding materials — meaning that once cured under heat and pressure, they formed rigid, chemically stable structures that could not be re-melted. This characteristic made phenolic compounds highly desirable in applications requiring dimensional stability, resistance to electrical arcing, and the ability to maintain structural integrity at elevated temperatures. RX466 and similar Rogers Corporation phenolic compounds were used in the production of electrical components, industrial housings, switchgear parts, circuit breaker components, and a range of other manufactured goods found across heavy industry, utilities, and electrical manufacturing sectors.
Rogers Corporation operated during decades when asbestos was a widely accepted and legally permissible additive to high-performance industrial materials. The company’s phenolic compound lines were developed and produced during a period in which regulatory oversight of asbestos in manufactured goods was limited, and industry standards routinely called for mineral reinforcement — including asbestos fiber — to enhance the thermal and mechanical properties of molded parts.
Asbestos Content
Asbestos was incorporated into phenolic molding compounds like RX466 as a functional reinforcing filler. In thermosetting resin systems of this type, asbestos fibers — most commonly chrysotile (white asbestos), though amphibole varieties were also used in industrial formulations — served multiple roles. The fibers improved the compound’s resistance to heat distortion, reduced brittleness, enhanced arc resistance in electrical applications, and contributed to the overall strength-to-weight characteristics of the finished molded part.
In phenolic resin manufacturing, asbestos was typically added during the compounding stage, where raw resin was blended with fillers, curing agents, pigments, and reinforcing fibers. The resulting mixture was then processed into molding powder or granules that could be shipped to fabricators and molded into finished components. Throughout this process, raw asbestos fiber and asbestos-laden compound existed in forms that could release respirable fibers into the air during handling, mixing, weighing, and molding operations.
Litigation records document that RX466 and related Rogers Corporation phenolic compounds contained asbestos as a formulated ingredient. The specific fiber type and concentration could vary by product grade and intended application, but litigation records document that asbestos content in such compounds was a deliberate design choice tied to the product’s performance characteristics rather than an incidental contaminant.
How Workers Were Exposed
Exposure to asbestos from RX466 high-heat phenolic compound occurred at multiple points along the product’s lifecycle, affecting workers in manufacturing facilities, fabrication shops, and industrial end-use environments.
Compounding and Processing Facilities: Workers involved in the manufacturing of phenolic molding compound — including those who weighed, measured, blended, and processed raw asbestos fiber into resin batches — faced the most direct and concentrated exposures. These operations generated fine airborne dust that could contain respirable asbestos fibers at significant concentrations. Industrial workers generally employed in these roles often worked in facilities where dust control measures were inadequate or absent during the mid-twentieth century.
Molding and Fabrication Workers: Downstream fabricators who received RX466 compound and processed it into finished parts were also at risk. Molding operations involving phenolic compounds could generate dust during material loading, press operation, and part trimming or deflashing. Workers who operated compression or transfer molding presses, or who finished or machined molded parts made from asbestos-containing phenolic compounds, were potentially exposed to asbestos fibers released from the material during these operations.
Maintenance and Industrial Workers: Finished components made from asbestos-containing phenolic compounds — such as electrical insulators, switchgear housings, or thermal barriers — could also release fibers when cut, drilled, abraded, or broken during maintenance, repair, or replacement activities. Industrial workers generally who encountered these components in plant maintenance roles may have been exposed through secondary contact with the finished product.
Plaintiffs alleged that Rogers Corporation knew or should have known of the hazards associated with asbestos-containing phenolic compounds and failed to provide adequate warnings to workers who handled, processed, or otherwise encountered RX466 and related products. Plaintiffs alleged that this failure to warn contributed directly to occupational asbestos disease among workers in industries that relied on these materials.
The occupational diseases associated with asbestos exposure include mesothelioma, a rare and aggressive cancer of the pleural and peritoneal linings that is causally linked to asbestos inhalation; asbestos-related lung cancer; asbestosis, a progressive and irreversible fibrotic lung disease; and other pleural conditions. These diseases typically have latency periods of twenty to fifty years between initial exposure and clinical diagnosis, meaning that workers exposed to RX466 compound decades ago may only now be receiving diagnoses.
Documented Trust Fund / Legal Options
RX466 is classified as a Tier 2 — Litigated product. No active asbestos bankruptcy trust fund has been identified specifically for Rogers Corporation in connection with this product. Claims related to RX466 and Rogers Corporation’s asbestos-containing phenolic compounds have been pursued through civil litigation in state and federal courts.
Litigation records document that plaintiffs diagnosed with mesothelioma, lung cancer, and other asbestos-related diseases have named Rogers Corporation in personal injury lawsuits arising from occupational exposure to its asbestos-containing phenolic compounds. Plaintiffs alleged product liability, failure to warn, and negligence theories in these cases.
Legal Options for Affected Workers and Families:
Civil Litigation: Workers or their survivors who can document occupational exposure to RX466 or related Rogers Corporation phenolic compounds and who have been diagnosed with a qualifying asbestos-related disease may have grounds to pursue a civil lawsuit. An experienced asbestos attorney can evaluate the exposure history, available documentation, and applicable statutes of limitations.
Additional Trust Claims: Workers exposed to RX466 in industrial settings may also have encountered asbestos-containing products from other manufacturers during their careers. Many of those manufacturers have since filed for bankruptcy and established asbestos trust funds. A comprehensive legal evaluation should review the full occupational history for potential claims against multiple parties and trusts.
Veterans’ Benefits: If exposure occurred during military service or in military-connected industrial environments, VA benefits for asbestos-related disease may be available independently of civil claims.
Individuals who believe they were exposed to RX466 or similar Rogers Corporation phenolic compounds should consult a qualified asbestos litigation attorney. Documentation of employment history, job duties, and workplace conditions is valuable to any claim. Medical records confirming an asbestos-related diagnosis should be preserved, and affected individuals should seek evaluation from a physician experienced in occupational lung disease.